Today: 21 July 2026
Beazley shares edge higher as hedge fund lifts bet ahead of Zurich deadline
24 February 2026
1 min read

Beazley shares edge higher as hedge fund lifts bet ahead of Zurich deadline

London, Feb 24, 2026, 08:43 GMT — Regular session

  • Beazley shares ticked up after new takeover-position disclosures surfaced.
  • Caxton Associates disclosed a larger net long, mostly through equity-linked swaps.
  • Zurich has until March 4 to make its cash offer official.

Shares of Beazley edged higher Tuesday, lifted 0.16% to 1,219 pence in early London trade, after a regulatory filing revealed Caxton Associates had built its stake in the insurer. Investors are shifting positions as a crucial takeover deadline approaches.

This disclosure is significant: Beazley remains in a formal “offer period” under the UK Takeover Code, requiring substantial shareholders and active traders to report their positions and trades. Zurich, still in discussions regarding a potential cash acquisition, faces a deadline of 5 p.m. London time on March 4 to either table a firm bid or step back, according to Beazley.

Beazley and Zurich said they’ve reached an agreement in principle on the financial terms for a possible recommended offer, pegging Beazley shares at as much as 1,335 pence apiece. That breaks down to 1,310 pence in cash and up to 25 pence in so-called “permitted” dividends before the deal is finalized. According to Beazley’s board, they’re inclined to back an offer at those levels, though final documents and other conditions still need to be worked out.

Caxton disclosed a 4.14% stake in Beazley, per its Form 8.3 filing, with most of that held via a cash-settled equity-linked swap. The firm upped its long position by 500,000 reference shares, priced at 12.22 pounds each. With cash-settled derivatives, there’s typically no delivery of shares—settlement happens in cash, a setup favored in merger arbitrage strategies.

Monday brought more of the same: Natixis SA, in a Feb. 20 filing, disclosed both long and short stakes in Beazley—each at 3.97% of the company’s shares.

During offer periods, banks file too, especially if they’re trading on behalf of clients. A case in point: Barclays Capital Securities listed its positions in Beazley via a Form 8.5 disclosure—those came from its market-making business.

Beazley shares hang below the headline price dangled in the possible offer—leaving a gap that tends to shift with fresh signals on timing, terms, or Zurich’s willingness to stick around. That’s the turf for the quicker money.

Plenty of obstacles remain. Zurich’s confirmatory due diligence is ongoing, and any formal bid would carry conditions—regulatory approvals among them. If negotiations drag, the Takeover Panel can quickly demand answers.

Traders keep a close eye on the steady stream of Rule 8 filings, trying to spot who’s accumulating size and if it’s happening in cash stock or through derivatives. The real test comes March 4—that’s the deadline for Zurich to lay out a firm bid or walk away.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Crypto Scams Cost Americans $11 Billion in 2025, FBI Warns, as Crypto ATM Losses Climb
    July 21, 2026, 2:46 AM EDT. Americans suffered losses exceeding $11.366 billion to cryptocurrency scams in 2025, according to figures from the FBI's IC3, registering 181,565 crypto-related complaints. Losses from investment fraud accounted for $7.2 billion tied to 61,559 cases. Losses traced to crypto kiosks totaled $389 million, up 58% from the prior year, disproportionately affecting individuals aged 60 and older. Spokane and Washington D.C. responded with measures such as a crypto ATM ban and legal actions targeting fraud.
Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod
Previous Story

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

USA Rare Earth (USAR) stock slips in premarket after 9% jump — what to watch next
Next Story

USA Rare Earth (USAR) stock slips in premarket after 9% jump — what to watch next

Go toTop